|
By
BioMedReports.Com
|
|
Sunday, 01 November 2015 21:30 |
 We are offering discounted subscription plans to join BioMedReports.com for a limited time.
|
|
Read more...
|
|
By
David Fowler
|
|
Tuesday, 15 September 2015 18:12 |
 Biopharmaceutical firm GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) has confirmed positive top line results from exploratory Phase 2a placebo-controlled clinical trial of Cannabidiol in 88 patients suffering from schizophrenia.
|
|
Read more...
|
|
By
Josh Gee
|
|
Wednesday, 09 September 2015 22:40 |
 Oncology-focused biopharmaceutical firm TESARO Inc(NASDAQ:TSRO) has confirmed that U.S. Food and Drug Administration (FDA) has given consent to VARUBI combined with other antiemetic agents in adults for avoiding delayed nausea and vomiting related to repeat courses of emetogenic cancer chemotherapy.
|
|
Read more...
|
|
By
David Fowler
|
|
Thursday, 20 August 2015 14:50 |
 Clinical stage drug development firm Corbus Pharmaceuticals Holdings Inc(NASDAQ:CRBP) has confirmed that U.S. Food and Drug Administration has given Fast Track development program the investigation of Resunab for systemic sclerosis.
|
|
Read more...
|
|
By
David Fowler
|
|
Wednesday, 05 August 2015 18:10 |
|
Leader of innovative therapies, La Jolla Pharmaceutical Company (NASDAQ:LJPC), has confirmed signing of two exclusive worldwide license agreements for intellectual property rights that would include La Jolla’s next-generation gentamicin derivatives, LJPC-30Sa and LJPC-30Sb.
|
|
Read more...
|
|
By
William Kent
|
|
Tuesday, 04 August 2015 17:22 |
 Leading developer of biocatalysts for pharma as well as chemical industries Codexis, Inc.(NASDAQ:CDXS) confirmed signing a CodeEvolver platform technology license agreement with Merck. Merck is known as MSD outside Canada as well as US.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Monday, 03 August 2015 17:21 |
 BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has confirmed that it would be getting statistical analysis of results from study that shows universal flu vaccine (M-001) of the firm, which was provided in BVX-005 phase II trial that had taken place three years back.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Thursday, 30 July 2015 14:50 |
 Clinical stage vaccine firm Novavax, Inc. (NASDAQ:NVAX) has confirmed positive top-line data from Phase 2clinical trial of the recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate.
|
|
Read more...
|
|
By
William Kent
|
|
Tuesday, 28 July 2015 20:08 |
 Biopharmaceutical firm Loxo Oncology Inc. (NASDAQ:LOXO) and the University of Colorado Cancer Center has confirmed publication of research brief in online edition of journal Cancer Discovery showing the patient with tropomyosin receptor kinase fusion cancer enrolled in Phase 1 dose escalation trial of LOXO-101, only selective TRK inhibitor in clinical development.
|
|
Read more...
|
|
By
William Kent
|
|
Friday, 24 July 2015 14:57 |
|
Biopharmaceutical firm ZIOPHARM Oncology Inc.(NASDAQ:ZIOP) Oncology has confirmed that U.S. Food and Drug Administration (FDA) has given approval to Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in treating the ones who suffer from malignant glioma.
|
|
Read more...
|
